Curis Q3 loss per share narrows 80% to $1.94
CRIS•Curis’ third-quarter 2026 loss per share narrowed 80% to $1.94, while net loss widened 5% year over year to $8.12 million. The company reported no revenue and said existing cash plus about $7.5 million in October private-placement proceeds are expected to fund operations into the first quarter of 2027.
1. Quarterly results and outlook
Curis reported a third-quarter 2026 net loss of $8.12 million, up 5% year over year, and no revenue following the sale of Erivedge royalties in the fourth quarter of 2025. Research and development expenses fell 13% to $5.6 million, primarily due to lower employee-related costs. Its TakeAim CLL study had enrolled 12 patients, with initial data expected in December 2026; existing cash and approximately $7.5 million in October private-placement net proceeds are expected to fund operations into the first quarter of 2027.
